CEO Garcia Marino sells entire 122,918-share position at $80.69–$85.53 for $10.0M; exits 100% holdings
Garcia Marino, CEO and President of Dianthus Therapeutics, executed 5 separate sales on 2026-03-12 totaling 122,918 shares (122.9K shares) for $10,016,380.63 ($10.0M), with a blended average price of $81.49. The transaction represents a complete liquidation: pre-transaction holdings were 122,918 shares; post-transaction holdings are 0 shares. This full exit occurs while the company faces severe operational headwinds: latest quarter revenue stands at $396,000.00 ($396.0K), full-year net income was negative ($-36,765,000.00), and annual revenue growth declined -67.4% year-over-year. The stock's 30-day change is +56.0% and 90-day change is +84.8%, placing current trading at $77.86, or -10.4% from the 52-week high of $86.92—near the peak of the recent rally. A complete liquidation by the chief executive officer at elevated prices, concurrent with a period of sharp revenue contraction and sustained unprofitability, is a material event requiring investor scrutiny.